Recall issues and isotope shortages weigh on Radnostix Q1 revenue
The radioisotope-focused company reported $2.38M in Q1 revenue, citing recall impacts, isotope shortages, and Cobalt-60 hot cell downtime.
Radnostix reported total revenue of $2.38M for the first quarter of 2026, down 27% from $3.24M in the same period of 2025. The quarter ended March 31.
Recall impacts, isotope shortages, and Cobalt-60 downtime drove the revenue decline, according to the company. Radnostix, formerly International Isotopes, manufactures radioisotope-focused products for medical, industrial, and research applications.
Gross profit fell 43% to $1.15M from $2.03M in the prior-year period. Radnostix attributed the decrease to recall impacts and changes in labor cost allocation.
Net loss widened to $1.35M, compared with a net loss of about $112,700 in Q1 2025. Adjusted EBITDA declined to -$0.92M from $0.12M, while operating expenses rose 7% to $2.46M.
During the quarter, Radnostix completed construction of a dedicated Calibration & Reference Products manufacturing facility and received an initial U.S. Nuclear Regulatory Commission license amendment for the site. The company said the facility is intended to support capacity expansion and product portfolio growth in 2026.
Commercial activity related to the Cobalt-60 hot cell resumed during Q1 after more than 5 months of downtime. Radnostix said the repair and retrofit work extended the asset’s useful life by 15 to 20 years.
Cash and cash equivalents stood at $1.35M at quarter-end, down from $1.70M on Dec. 31, 2025. Net cash used in operating activities was $72,442 for the quarter.
Radnostix operates across theranostics, nuclear medicine, industrial isotope applications, and radiation safety. Its investor materials describe the company as a supplier to hospitals, radiopharmacies, imaging centers, and research institutions.
Company:Radnostix
About the author
RadiologySignal.com writersEditorial Team
Radiology Signal Staff covers developments across medical imaging, radiology AI, imaging informatics, clinical research, and radiology business. The team monitors primary sources, peer-reviewed studies, company announcements, society updates, and healthcare industry news to deliver concise reporting for imaging professionals.
More from this section
Pathology support broadens MedDream viewer scope
Version 8.9.0 is scheduled for June 2026 through aycan and will add support for pathology workflows and saving reconstructed MPR viewports as new study series.
DOSIsoft unit gives PLANET a theranostics focus
DOSIsoft Theranostics will operate within the DOSIsoft group, with its own partnerships and investment strategy centered on PLANET software.
I-MED sale gives Jardines 215-clinic radiology network
Jardine Matheson will acquire 100% of I-MED Radiology Network in a deal valued at A$3.4B, including I-MED’s minority stake in Harrison.ai.
Expected Russell addition puts Hyperfine in small-cap benchmarks
FTSE Russell’s preliminary June reconstitution list includes Hyperfine, with index changes set to take effect after U.S. markets close on June 26.
Curium approach puts Lantheus deal value near $7B
Lantheus is weighing a potential sale after an approach from Curium Pharma, while company filings show recent Pylarify pressure and pending PET regulatory milestones.
Niowave Lansing site to scale Ac-225 supply by 2028
The Lansing, MI, site will house superconducting linear accelerators and radiochemistry systems to support scalable actinium-225 production, with completion expected in 2028.
30-year GE-UW tie expands into CT and theranostics research
The collaboration will focus on CT and molecular imaging technologies for cardiology, oncology, and theranostics workflows at UW Medicine Radiology facilities in Seattle.
Ephemeral to build AI data platform for Plus CNS oncology programs
The companies will develop an AI platform to integrate therapeutic, diagnostic, and bioinformatics data across Plus Therapeutics’ CNS oncology programs.
Fujifilm balloon-free EBUS scope targets pulmonary setup time
The EB-710US Ultrasound Bronchoscope is designed for pulmonary procedures and will be demonstrated at the American Thoracic Society Conference.
ACIST Pro brings contrast tracking upgrade to U.S. cath labs
The Bracco company received U.S. clearance and launched ACIST Pro, a variable-rate contrast management system for image-guided cardiovascular procedures.
Braid Health launches $199 radiology second-opinion service
Patients can upload MRI, CT, X-ray, or ultrasound files and receive a written second opinion from a board-certified U.S. radiologist.
QT Imaging prices $10M raise for breast imaging platform
QT Imaging Holdings priced a $10M underwritten public offering of common stock and pre-funded warrants. The breast imaging technology company plans to use proceeds for working capital and general corporate purposes.